Harder et al., “Clinically Important Drug Interactions with Anticoagulants”, Clin. Pharmacokinet., (1996) 30, pp. 416-444. |
Verstraete et al., “Novel Antithrombotic Drugs in Development”, Drugs, (1996) 49, pp. 856-884. |
Bouygues, et al., “Syntheses of new modified Phe-Pro peptides”, Bioorg. Med. Chem. Lett., 8, (1998), pp. 277-280. |
Wells, et al., “Regioselective Nucleophilic Substitutions of Fluorobenzene Derivatives”, Tetrahedron Letters, (1996), 37, No. 36, pp. 6439-6442. |
Makosza, et al., “Hydroxylation of Nitroarenes with Alkyl Hydroperoxide Anions via Vicarious Nucleophilic Substitution of Hydrogen”, J. Org. Chem. (1998), 63, pp. 4199-4208. |
Coutrot et al., “2-Diethoxyphosphoryl alcanoic acid dianions (lithium α-lithiocarboxylates)”, Journal of Organometallic Chemistry, (1987), 332, pp. 1-8. |
Hara, et al., “DX-9065a, a New Synthetic, Potent Anticoagulant and Selective Inhibitor for Factor Xa”, Thombosis and Haemostasis, (1994), 71, pp. 314-319. |
Taniuchi, et al, “Biochemical and Pharmacological Characterization of YM-60828, a Newly Synthesized and Orally Active Inhibitor of Human Factor Xa”, Thromb Haemost, (1998), 79, pp. 543-548. |
Drugs, 53, 736 (1997). |
N. Engl. J. Med., 333, 1588 (1995). |
Circulation, 98, 287 (1998). |
Drugs, 52, 276 (1996). |
Thromb. Res., 86, 1 (1997). |
J. Enzyme Inhibition, 14, 15 (1998). |